

# Challenges and Rewards of AI Software Applications in Pathology

BEATRICE KNUDSEN, M.D. – PH.D.  
MEDICAL DIRECTOR OF DIGITAL AND COMPUTATIONAL PATHOLOGY  
ARUP NATIONAL REFERENCE LABORATORIES

Park City, Feb. 9<sup>th</sup> 2022

1

---

---

---

---

---

---

---

---

Nothing to disclose related to this presentation

2

---

---

---

---

---

---

---

---

## The case management cockpit

- ▶ Access to all data associated with diagnosis workup
- ▶ Clinical workup data sources:
  - Pathology slides and report
  - Laboratory test data
  - Radiology report and images
  - Electronic medical record system
- ▶ Pathology imaging data sources
  - Gross room images, light microscopy, fluorescent microscopy, electron microscopy
  - Laboratory medicine images: gel electrophoresis, bacterial/viral cultures, Ova & Parasites, etc.

3

---

---

---

---

---

---

---

---






# Clinical implementation of digital pathology requires a team

## CHALLENGES for DIGITAL pathology

- ▶ Integration of the digital pathology computer and software systems with other laboratory information systems in pathology



10

---

---

---

---

---

---


---

---

# Clinical implementation of digital pathology requires a team

## CHALLENGES for COMPUTATIONAL pathology

- ▶ To bring research grade algorithms into clinical practice



11

---

---

---

---

---

---

---

---

# Why should pathologists adopt digital pathology ?

- ▶ Efficiency
- ▶ Accuracy
- ▶ Structured, accessible information and slide organization
- ▶ Job satisfaction of pathologists and lab personnel
- ▶ Client satisfaction
- ▶ Improved communication
- ▶ Research opportunities
- ▶ Education



12

---

---

---

---

---

---

---

---

## Resistance to digital sign out in pathology

- ▶ Distrust of algorithm and computer assistance
- ▶ Less control over sign out process
- ▶ Less interactions with colleagues
- ▶ Speed
- ▶ Ergonomics
- ▶ Joy of microscopy
- ▶ Change in workflow



13

---

---

---

---

---

---

---

---

## How to overcome resistance and move to a digital sign out

- ▶ Partnership between pathologists
- ▶ Discovering value in DP
- ▶ Educational materials
- ▶ Partnership with slide management systems vendor
- ▶ Customized interfaces
- ▶ High-quality DP products (requires evaluation)
- ▶ Internet speed and ergonomics



14

---

---

---

---

---

---

---

---

## What do I need to sign out cases at home

1. March 2020, CMS temporarily waived the requirement for remote locations to have separate CLIA licenses. Advocacy by CAP committees to convert temporary to permanent regulation.
2. The validation study using 60 H&E cases and 20 IHC cases with glass and digital reads. > 95% concordance for diagnostic components affecting patient management
3. Remote readiness:
  - Computer/workstation with large monitor and fast network bandwidth
  - Remote desktop connection through institutional virtual private network with 2-factor authentication

15

---

---

---

---


---

---

---

---

## Digital Pathology and education



BRITISH  
**DPA**  
ASSOCIATION

### Digital Anatomic Pathology Academy

Cloud-based platform which provides annotated digital slides with diagnosis and relevant information of morphology and ancillary testing

16

---

---

---

---

---

---

---

---

---

---

## Digital pathology and regulatory science



A regulatory science initiative to harmonize and standardize digital pathology processes to speed up innovation to patients.

### Pathology Innovation Collaborative Community

The Alliance for Digital Pathology and AI/ML



PIOC is a collaborative community that provides the infrastructure to connect stakeholders



17

---

---

---

---

---

---

---

---

---


---

## Value proposition of digital pathology

### Shortage of pathologists



### Value for computational pathology



18

---

---

---

---

---

---


---

---

---

---

# What is computational pathology ?



19

---

---

---

---

---

---

---


---

# FDA approves algorithm for prostate cancer diagnosis



September 21<sup>st</sup>, 2021

- ▶ Algorithm can be used as second opinion for cancer detection
- ▶ approval based on a study where 4 pathologists examined 527 digitally scanned prostate biopsy slides. The pathologist made two assessments, one with and one without the program's help.
- ▶ The software improved detection of cancer on individual slide images by 7.3% on average compared to unassisted reads.



IBEX

20

---

---

---

---

---


---

---

---

# How do machine learning algorithms work ?

- Level 1 : counting positive cells in IHC stained slides
- Level 2 : cancer diagnosis and outline of cancer regions
- Level 3 : prognosis and treatment recommendation



Predicting cancer outcomes from histology and genomics using convolutional networks. Moadabersany & Lee Cooper PNAS, 2018

21

---

---

---

---


---

---

---

---

## Pathologist-inspired algorithm development



- Criteria established by pathologist do diagnose prostate cancer:
  - Loss of basal cell layer
  - Nuclear enlargement
  - Nucleolus
  - Luminal border
- Force algorithm to learn features of these criteria
- Visualize features that the algorithm learned
- This specific approach does not work for grading, which is based on gland architecture

22

---

---

---

---

---

---

---


---

---

---

## IHC quantification

- FDA approved algorithms since 2007
- Algorithm linked to slide scanner
- Home – grown systems
- Semi-automated, pathologists marks region to quantify
- Ki-67, breast panel, PD-L1




Modern Pathology 2018 32:1248–1256  
 doi:10.1038/s41379-018-0276-4

USCAP

ARTICLE

Combined quantitative measures of ER, PR, HER2, and Ki67 provide more prognostic information than categorical combinations in luminal breast cancer

Muntopha Abubakar<sup>1,2</sup>, Janine Figueras<sup>3</sup>, H. Raza Asif<sup>4</sup>, Florio Blows<sup>5</sup>, Julanta Litowska<sup>6</sup>, Carlos Cabello<sup>1,2</sup>, Douglas F. Easton<sup>1,2</sup>, Mark E. Sherman<sup>1,2</sup>, Montserrat Garcia-Closas<sup>1</sup>, Mitch Dowsett<sup>1,7</sup>, Paul D. Pharoah<sup>1,2</sup>



23

---

---

---

---

---

---

---

---

---

---

## Automated PD-L1 scoring workflow

24

---

---

---

---

---

---

---


---

---

---



Step 1- The computer learns to overlap images from different slides



H&E PD-L1 negative control PD-L1

Step 2: outline areas of necrosis

25

---

---

---

---


---

---

---

---

Step 3 - Computer learns to outline cancer regions



Original image Computer generated cancer map

Red: Cancer  
Blue: Non-cancer

26

---

---

---

---


---

---

---

---

Examples of computer-generated annotations in IHC slides – step 4



Nuclear outlines and immune cell infiltration

27

---

---

---

---


---

---

---

---

## Quantification of PD-L1 positive cells – step 5



28

---

---

---

---

---

---

---

---

## Performance evaluation of the algorithm is critical at your practice location

- ▶ Don't trust vendors (yet)
- ▶ Algorithms are challenging to optimize
- ▶ Off the shelf commercial algorithm need to be tested at your practice location for its performance
- ▶ Performance has to be evaluated for each step in the algorithm if there is a problem with the algorithm
- ▶ Be involved in testing to understand what the algorithm does
- ▶ Data migration into pathology reports

29

---

---

---

---

---

---

---

---

## Future opportunities in digital and computational pathology

- ▶ Automation of anatomic pathology
- ▶ Increased efficiency
- ▶ Increased accuracy (reimbursement for using algorithm)
- ▶ Fast second opinion
- ▶ Quantitative data from slides
- ▶ Prognostic and treatment related information
- ▶ May be able to replace certain expensive genomic testing

30

---

---

---

---

---

---

---

---

## Future challenges in digital and computational pathology

- ▶ Expensive infrastructure
- ▶ Integration into existing IT structure
- ▶ New operational workflows
- ▶ Acceptance by pathologists
- ▶ Regulatory framework
- ▶ Pricing and cost efficiency

31

---

---

---

---

---

---

---

---

Thank you for your attention

QUESTIONS ?

32

---

---

---

---

---

---

---

---